<?xml version="1.0" encoding="UTF-8"?>
<ref id="B38-vaccines-08-00115">
 <label>38.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jacca</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Rolih</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Quaglino</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Franceschi</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Tebaldi</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Bolli</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Rosamilia</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ottonello</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Cavallo</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Donofrio</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer</article-title>
  <source>Oncoimmunology</source>
  <year>2016</year>
  <volume>5</volume>
  <fpage>e1082705</fpage>
  <pub-id pub-id-type="doi">10.1080/2162402X.2015.1082705</pub-id>
  <pub-id pub-id-type="pmid">27141335</pub-id>
 </element-citation>
</ref>
